Equities Analysts Offer Predictions for BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Analysts at Erste Group Bank raised their FY2026 earnings estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $6.34 per share for the year, up from their previous estimate of $6.31. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.34 per share.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

BMY has been the subject of several other research reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $60.89 on Monday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a market cap of $124.34 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $62.89. The company’s 50-day moving average price is $57.20 and its two-hundred day moving average price is $57.90.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Institutional Trading of Bristol Myers Squibb

Several hedge funds have recently modified their holdings of BMY. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank boosted its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the second quarter worth about $221,000. Finally, Nebula Research & Development LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth about $405,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA collaboration and plans to deploy a next-generation DGX SuperPOD AI system to speed drug discovery, a potentially positive long-term productivity and innovation catalyst. Article Title
• Positive Sentiment: The company said it will be the first life sciences firm to buy NVIDIA’s DGX SuperPOD based on Vera Rubin systems, highlighting an aggressive push into advanced AI infrastructure for drug development. Article Title
• Positive Sentiment: Bristol Myers is also being viewed as a peer in next-generation cancer treatment innovation, with its bispecific antibody work alongside BioNTech mentioned in coverage of therapies that could help replace older blockbuster drugs over time. Article Title
• Neutral Sentiment: Healthcare stocks traded lower late Monday afternoon, which could have offset some of the positive company-specific momentum in BMY. Article Title

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.